Endothelial monocyte activating polypeptide II (EMAP II) enhances the effect of TNF on tumor-associated vasculature

M. L. Kayton, S. K. Libutti

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Endothelial monocyte activating polypeptide II (EMAP II) was initially identified as a factor that may modulate the interaction of tumor necrosis factor (TNF) with tumor vascular endothelium. Since the toxicity of TNF has continued to hamper its clinical use in cancer patients, investigators have developed a renewed interest in modulators such as EMAP II. Over a period of 25 years, investigations into the mechanism of antitumor action of TNF have yielded important observations concerning the role of the microvasculature as the target for TNF's activity. EMAP II was identified as an endothelial response mediator secreted by a highly TNF-sensitive tumor line, the Meth A fibrosarcoma. When used to treat tumors, either by systemic administration of recombinant protein or by gene transfer, EMAP II upregulates cellular receptors for TNF on endothelial cells and confers TNF sensitivity to tumors previously believed to be TNF-resistant. Potential mechanisms for EMAP II's selective effects on endothelial cells have been described. These include induction of endothelial cell apoptosis and upregulation of TNF receptor I (TNFR1). Other recent investigations have posited various physiological roles for EMAP II, ranging from the mediation of inflammation to the vascular remodeling that occurs during normal embryogenesis. EMAP II has generated interest as a modulator of TNF response for isolated whole-organ, isolated limb, or systemic perfusion. By enhancing the tumor vasculature response to TNF, EMAP II may enable lower, non-toxic doses of TNF to be used to clinical advantage.

Original languageEnglish (US)
Pages (from-to)136-138
Number of pages3
JournalCurrent Opinion in Investigational Drugs
Volume2
Issue number1
StatePublished - 2001
Externally publishedYes

Fingerprint

Tumor Necrosis Factor-alpha
Neoplasms
Endothelial Cells
Tumor Necrosis Factor Receptors
Up-Regulation
Receptors, Tumor Necrosis Factor, Type I
small inducible cytokine subfamily E, member 1
Fibrosarcoma
Vascular Endothelium
Microvessels
Recombinant Proteins
Embryonic Development
Extremities
Perfusion
Research Personnel
Apoptosis
Inflammation
Genes

Keywords

  • Endothelial monocyte activating polypeptide II
  • Isolated limb perfusion
  • Isolated whole-organ perfusion
  • Tissue factor
  • Tumor endothelium
  • Tumor necrosis factor

ASJC Scopus subject areas

  • Pharmacology

Cite this

Endothelial monocyte activating polypeptide II (EMAP II) enhances the effect of TNF on tumor-associated vasculature. / Kayton, M. L.; Libutti, S. K.

In: Current Opinion in Investigational Drugs, Vol. 2, No. 1, 2001, p. 136-138.

Research output: Contribution to journalArticle

@article{d769a812864242ab90d7e48582bb6eae,
title = "Endothelial monocyte activating polypeptide II (EMAP II) enhances the effect of TNF on tumor-associated vasculature",
abstract = "Endothelial monocyte activating polypeptide II (EMAP II) was initially identified as a factor that may modulate the interaction of tumor necrosis factor (TNF) with tumor vascular endothelium. Since the toxicity of TNF has continued to hamper its clinical use in cancer patients, investigators have developed a renewed interest in modulators such as EMAP II. Over a period of 25 years, investigations into the mechanism of antitumor action of TNF have yielded important observations concerning the role of the microvasculature as the target for TNF's activity. EMAP II was identified as an endothelial response mediator secreted by a highly TNF-sensitive tumor line, the Meth A fibrosarcoma. When used to treat tumors, either by systemic administration of recombinant protein or by gene transfer, EMAP II upregulates cellular receptors for TNF on endothelial cells and confers TNF sensitivity to tumors previously believed to be TNF-resistant. Potential mechanisms for EMAP II's selective effects on endothelial cells have been described. These include induction of endothelial cell apoptosis and upregulation of TNF receptor I (TNFR1). Other recent investigations have posited various physiological roles for EMAP II, ranging from the mediation of inflammation to the vascular remodeling that occurs during normal embryogenesis. EMAP II has generated interest as a modulator of TNF response for isolated whole-organ, isolated limb, or systemic perfusion. By enhancing the tumor vasculature response to TNF, EMAP II may enable lower, non-toxic doses of TNF to be used to clinical advantage.",
keywords = "Endothelial monocyte activating polypeptide II, Isolated limb perfusion, Isolated whole-organ perfusion, Tissue factor, Tumor endothelium, Tumor necrosis factor",
author = "Kayton, {M. L.} and Libutti, {S. K.}",
year = "2001",
language = "English (US)",
volume = "2",
pages = "136--138",
journal = "Current Opinion in Investigational Drugs",
issn = "1354-3784",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Endothelial monocyte activating polypeptide II (EMAP II) enhances the effect of TNF on tumor-associated vasculature

AU - Kayton, M. L.

AU - Libutti, S. K.

PY - 2001

Y1 - 2001

N2 - Endothelial monocyte activating polypeptide II (EMAP II) was initially identified as a factor that may modulate the interaction of tumor necrosis factor (TNF) with tumor vascular endothelium. Since the toxicity of TNF has continued to hamper its clinical use in cancer patients, investigators have developed a renewed interest in modulators such as EMAP II. Over a period of 25 years, investigations into the mechanism of antitumor action of TNF have yielded important observations concerning the role of the microvasculature as the target for TNF's activity. EMAP II was identified as an endothelial response mediator secreted by a highly TNF-sensitive tumor line, the Meth A fibrosarcoma. When used to treat tumors, either by systemic administration of recombinant protein or by gene transfer, EMAP II upregulates cellular receptors for TNF on endothelial cells and confers TNF sensitivity to tumors previously believed to be TNF-resistant. Potential mechanisms for EMAP II's selective effects on endothelial cells have been described. These include induction of endothelial cell apoptosis and upregulation of TNF receptor I (TNFR1). Other recent investigations have posited various physiological roles for EMAP II, ranging from the mediation of inflammation to the vascular remodeling that occurs during normal embryogenesis. EMAP II has generated interest as a modulator of TNF response for isolated whole-organ, isolated limb, or systemic perfusion. By enhancing the tumor vasculature response to TNF, EMAP II may enable lower, non-toxic doses of TNF to be used to clinical advantage.

AB - Endothelial monocyte activating polypeptide II (EMAP II) was initially identified as a factor that may modulate the interaction of tumor necrosis factor (TNF) with tumor vascular endothelium. Since the toxicity of TNF has continued to hamper its clinical use in cancer patients, investigators have developed a renewed interest in modulators such as EMAP II. Over a period of 25 years, investigations into the mechanism of antitumor action of TNF have yielded important observations concerning the role of the microvasculature as the target for TNF's activity. EMAP II was identified as an endothelial response mediator secreted by a highly TNF-sensitive tumor line, the Meth A fibrosarcoma. When used to treat tumors, either by systemic administration of recombinant protein or by gene transfer, EMAP II upregulates cellular receptors for TNF on endothelial cells and confers TNF sensitivity to tumors previously believed to be TNF-resistant. Potential mechanisms for EMAP II's selective effects on endothelial cells have been described. These include induction of endothelial cell apoptosis and upregulation of TNF receptor I (TNFR1). Other recent investigations have posited various physiological roles for EMAP II, ranging from the mediation of inflammation to the vascular remodeling that occurs during normal embryogenesis. EMAP II has generated interest as a modulator of TNF response for isolated whole-organ, isolated limb, or systemic perfusion. By enhancing the tumor vasculature response to TNF, EMAP II may enable lower, non-toxic doses of TNF to be used to clinical advantage.

KW - Endothelial monocyte activating polypeptide II

KW - Isolated limb perfusion

KW - Isolated whole-organ perfusion

KW - Tissue factor

KW - Tumor endothelium

KW - Tumor necrosis factor

UR - http://www.scopus.com/inward/record.url?scp=0035148890&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035148890&partnerID=8YFLogxK

M3 - Article

C2 - 11527006

AN - SCOPUS:0035148890

VL - 2

SP - 136

EP - 138

JO - Current Opinion in Investigational Drugs

JF - Current Opinion in Investigational Drugs

SN - 1354-3784

IS - 1

ER -